GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (NAS:CTXR) » Definitions » Quick Ratio

Citius Pharmaceuticals (Citius Pharmaceuticals) Quick Ratio : 5.06 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Citius Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Citius Pharmaceuticals's quick ratio for the quarter that ended in Dec. 2023 was 5.06.

Citius Pharmaceuticals has a quick ratio of 5.06. It generally indicates good short-term financial strength.

The historical rank and industry rank for Citius Pharmaceuticals's Quick Ratio or its related term are showing as below:

CTXR' s Quick Ratio Range Over the Past 10 Years
Min: 0.05   Med: 1.65   Max: 35.17
Current: 5.06

During the past 13 years, Citius Pharmaceuticals's highest Quick Ratio was 35.17. The lowest was 0.05. And the median was 1.65.

CTXR's Quick Ratio is ranked better than
62.93% of 1554 companies
in the Biotechnology industry
Industry Median: 3.485 vs CTXR: 5.06

Citius Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Citius Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Pharmaceuticals Quick Ratio Chart

Citius Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.72 3.41 18.29 9.84 5.95

Citius Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.33 5.62 7.10 5.95 5.06

Competitive Comparison of Citius Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, Citius Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Citius Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Citius Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Citius Pharmaceuticals's Quick Ratio falls into.



Citius Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Citius Pharmaceuticals's Quick Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Quick Ratio (A: Sep. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(34.37-0)/5.779
=5.95

Citius Pharmaceuticals's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(28.21-0)/5.579
=5.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Citius Pharmaceuticals  (NAS:CTXR) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Citius Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Citius Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Citius Pharmaceuticals (Citius Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Executives
Myron Z Holubiak director, officer: Vice Chairman C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754
Dennis M Mcgrath director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Leonard L Mazur director, 10 percent owner, officer: Chief Executive Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Suren G Dutia director C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754
Carol Webb director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016
Eugene Myron Holuka director 11 COMMERCE DRIVE, 11TH FLOOR, CRANFORD NJ 07016
Jaime Bartushak officer: Chief Financial Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Myron Czuczman officer: Chief Medical Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Howard Safir director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016
William Kane director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016

Citius Pharmaceuticals (Citius Pharmaceuticals) Headlines